# Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

> **NCT07460362** · PHASE2 · RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 43 (estimated)

## Conditions studied

- MCL
- Relapsed or Refractory Mantle Cell Lymphoma (MCL)

## Interventions

- **DRUG:** Glofitamab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT07460362
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-11
- **Primary completion:** 2027-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07460362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07460362, "Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07460362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*